A randomized double-blind placebo-controlled trial on the effect of magnesium oxide in patients with chronic constipation

다국어 초록 (Multilingual Abstract)

Background/Aims

Magnesium oxide (MgO) has been frequently used as a treatment for chronic constipation (CC) since the 1980s in Japan. The aim of this study is to evaluate its therapeutic effects of MgO in Japanese CC patients.








Methods

We conducted a randomized, double-blind placebo-controlled study. Thirty-four female patients with mild to moderate constipation were randomly assigned to either placebo (n = 17) or MgO group (n = 17) 0.5 g × 3/day for 28 days. Primary endpoint was overall improvement over the 4-week study period. Secondary endpoints were changes from baseline in spontaneous bowel movement (SBM), response rates of complete spontaneous bowel movement (CSBM), stool form, colonic transit time (CTT), abdominal symptom, and quality of life.








Results

One patient failed to complete the medication regimen and was omitted from analysis: data from 16 placebo and 17 MgO patients were analyzed. The primary endpoint was met by 25.0% of placebo vs 70.6% of MgO group (P = 0.015). MgO significantly improved SBM changes compared to placebo (P = 0.002). However, MgO did not significantly improved response rates of CSBM compared to placebo (P = 0.76). In addition, MgO significantly improved Bristol stool form scale changes (P < 0.001) and significantly improved CTT compared to the placebo group (P < 0.001). MgO significantly improved the Japanese version of the patient assessment of constipation quality of life (P = 0.003).








Conclusion

Our placebo-controlled study demonstrated that MgO was effective treatment for improving defecation status and shortened CTT in Japanese CC patients with mild to moderate symptoms.

다국어 초록 (Multilingual Abstract)

Background/Aims

Magnesium oxide (MgO) has been frequently used as a treatment for chronic constipation (CC) since the 1980s in Japan. The aim of this study is to evaluate its therapeutic effects of MgO in Japanese CC patients.

Methods

We conducted a randomized, double-blind placebo-controlled study. Thirty-four female patients with mild to moderate constipation were randomly assigned to either placebo (n = 17) or MgO group (n = 17) 0.5 g × 3/day for 28 days. Primary endpoint was overall improvement over the 4-week study period. Secondary endpoints were changes from baseline in spontaneous bowel movement (SBM), response rates of complete spontaneous bowel movement (CSBM), stool form, colonic transit time (CTT), abdominal symptom, and quality of life.

Results

One patient failed to complete the medication regimen and was omitted from analysis: data from 16 placebo and 17 MgO patients were analyzed. The primary endpoint was met by 25.0% of placebo vs 70.6% of MgO group (P = 0.015). MgO significantly improved SBM changes compared to placebo (P = 0.002). However, MgO did not significantly improved response rates of CSBM compared to placebo (P = 0.76). In addition, MgO significantly improved Bristol stool form scale changes (P < 0.001) and significantly improved CTT compared to the placebo group (P < 0.001). MgO significantly improved the Japanese version of the patient assessment of constipation quality of life (P = 0.003).

Conclusion

Our placebo-controlled study demonstrated that MgO was effective treatment for improving defecation status and shortened CTT in Japanese CC patients with mild to moderate symptoms.

참고문헌 (Reference)

1 Gray JR, "What is chronic constipation? Definition and diagnosis" 25 (25): 7B-10B, 2011

2 Nomura H, "Validity and reliability of the Japanese version of the patient assessment of constipation quality of life questionnaire" 49 : 667-673, 2014

3 Turner-Bowker DM, "Usefulness of the SF-8 health survey for comparing the impact of migraine and other conditions" 12 : 1003-1012, 2003

4 Lembo AJ, "Two randomized trials of linaclotide for chronic constipation" 365 : 527-536, 2011

5 Cummings JH, "Transit through the gut measured by analysis of a single stool" 17 : 219-223, 1976

6 Tsunoda A, "The translation and validation of the Japanese version of the patient assessment of constipation quality of life scale" 46 : 414-421, 2016

7 Wald A, "The burden of constipation on quality of life : results of multinational survey" 26 : 227-236, 2007

8 Metcalf AM, "Simplified assessment of segmental colonic transit" 92 : 40-47, 1987

9 Nakajima A, "Safety and efficacy of elobixibat for chronic constipation : results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3trial" 3 : 537-547, 2018

10 The Japanese Society of Gastroenterology, "Research society for the Diagnosis and Treatment of Chronic Constipation, Affiliated to The Japanese Society of Gastroenterology in Japanese" Nankodo Co, Ltd 2017

11 Horibata K, "Relationship between renal function and serum magnesium concentration in elderly outpatients treated with magnesium oxide" 16 : 600-605, 2016

12 Akio Tamura, "Prevalence and Self-recognition of Chronic Constipation: Results of an Internet Survey" 대한소화기 기능성질환∙운동학회 22 (22): 677-685, 2016

13 Mertz H, "Physiology of refractory chronic constipation" 94 : 609-615, 1999

14 Donovan JL, "Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer" 375 : 1425-1437, 2016

15 Johanson JF, "Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation" 103 : 170-177, 2008

16 Basch E, "Methods for implementing and reporting patient-reported outcome(PRO)measures of symptomatic adverse events in cancer clinical trials" 38 : 821-830, 2016

17 Fukudo S, "Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation" 13 : 94-301, e5, 2015

18 Yamasaki M, "Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy" 70 : 921-924, 2014

19 Ministry of Health, Labour and Walfare, "Hypermagnesaemia caused by magnesium oxide" Pharmaceuticals and Medical Devices Safety Information

20 Tillou J, "Functional disorders : slow-transit constipation" 30 : 76-86, 2017

21 Longstreth GF, "Functional bowel disorders" 130 : 1480-1491, 2006

22 Alame AM, "Evaluation of constipation" 25 : 5-11, 2012

23 Pemberton JH, "Evaluation and surgical treatment of severe chronic constipation" 214 : 403-411, 1991

24 Fukudo S, "Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome : a randomized, placebo-controlled and dose-finding study" 23 : 544-e205, 2011

25 Rao SS, "Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation" 12 : 616-623, 2014

26 Tack J, "Diagnosis and treatment of chronic constipation a European perspective" 23 : 697-710, 2011

27 Marquis P, "Development and validation of the patient assessment of constipation quality of life questionnaire" 40 : 540-551, 2005

28 O’Donnell LJ, "Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate" 300 : 439-440, 1990

29 Chatoor D, "Constipation and evacuation disorders" 23 : 517-530, 2009

30 Sakimura K, "Clinical evaluation of YO-106(magnesium oxide tablets)in the treatment of habitual constipation–a cross over study with magnesium oxide powders" 26 : 1027-1053, 1998

31 Lacy BE, "Chronic constipation : new diagnostic and treatment approaches" 5 : 233-247, 2012

32 Lembo A, "Chronic constipation" 349 : 1360-1368, 2003

33 Lacy BE, "Bowel Disorders" 150 : 1393-1407, e5, 2016

34 Tokuda Y, "Assessing items on the SF-8 Japanese version for health-related quality of life : a psychometric analysis based on the nominal categories model of item response theory" 12 : 568-573, 2009

35 American College of Gastroenterology Chronic Constipation Task Force, "An evidence-based approach to the management of chronic constipation in North America" 100 (100): S1-S4, 2005

36 Bharucha AE, "American gastroenterological association technical review on constipation" 144 : 218-238, 2013

37 Christie J, "A randomized, double-blind, placebo-controlled trial to examine the effectiveness of lubiprostone on constipation symptoms and colon transit time in diabetic patients" 112 : 356-364, 2017

38 Chey WD, "A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation" 106 : 1803-1812, 2011

39 Fukudo S, "A randomized controlled and longterm linaclotide study of irritable bowel syndrome with constipation patients in Japan" 30 : e13444-, 2018

40 Agachan F, "A constipation scoring system to simplify evaluation and management of constipated patients" 39 : 681-685, 1996

41 Rao S, "A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation" 107 : 1714-1724, 2012